Research that Identifies
Undiscovered Value in the MicroCap Market


Catasys, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Research Update Released (Dated 12/08/2017)

Symbol: CATS
Analyst: John Nobile
Taglich Rating: Speculative Buy
Price Target: $5.30
Time Horizon: 12 Months
Rating Established: October 17, 2017
Price When Established: $3.93
Most Recent Report: December 8, 2017
Price When Issued: $3.55

What's New

Catasys Reports Q4 Results

On March 7, 2018, Catasys, Inc. (NASDAQ: CATS) reported results for its fourth quarter ended December 31, 2017.

For the quarter, the company reported that revenue decreased 19.9% to $3 million. Catasys reported a net loss of $2.7 million or $(0.17) per share versus a net loss of $1.5 million or $(0.16) per share in the comparable quarter in 2016.

Taglich Brothers’ estimates were for fourth quarter revenue of $3 million and a net loss of $1.4 million or $(0.09) per share.

Catasys Announces Agreement with Cigna

On January 16, 2018, Catasys, Inc. (NASDAQ: CATS) announced it entered into an agreement with Cigna Corporation for Catasys’ OnTrak solution for certain members with anxiety, depression or substance use disorders. The first market is expected to launch in 1Q18.

With the Cigna agreement, the company has now signed 6 of the 8 largest health plans in the US, and its OnTrak program is currently available in 19 states.

Company Description

Catasys, headquartered in Los Angeles, California, provides specialized behavioral health management and integrated treatment services to health plans through its proprietary OnTrak™ solution. OnTrak utilizes proprietary analytics in integrating medical and psychosocial treatments with care coaching in a 52-week outpatient program. OnTrak is designed to improve a member’s health while lowering costs to the insurer where behavioral health conditions are causing or exacerbating medical conditions.

Company Reports

Research Update Released (Dated December 8, 2017)

Initial Research Report (Dated October 17, 2017)


Please view our current disclosure and disclaimer on our most recent research report.